Under the terms of the agreement Richter will acquire the outstanding 49% stake in the next 3 years. According to the agreement Richter is obliged to pay an initial payment to Mediplus linked to the acquisition of the majority stake. Further milestone payments are connected to certain performance related targets to be reached by Mediplus.

Mediplus is a well established marketing company, which covers through its subsidiaries a number of countries in the Latin American region, namely: Ecuador, Peru, Chile and Bolivia. It also sells pharmaceutical products to Central American and Caribbean countries. The main profile of Mediplus is to market those female healthcare products of Richter, which are already on the market in the above mentioned countries and also to register other gynaecological products, including Esmya®.

Following the two acquisitions in Brazil and in Mexico announced late 2013, this transaction could be considered as a further step towards getting our foothold in Latin America, one of the fastest growing regions in the world and at the same time to become step by step a global female healthcare player in the pharmaceutical business.

About Gedeon Richter Plc.

Gedeon Richter Plc. (www.richter.hu) headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter’s consolidated sales were approximately EUR 1.2 billion (USD 1.6 billion) while its market capitalization amounted to EUR 2.8 billion (USD 3.8 billion) in 2013. The product portfolio of the Company covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular. Having the largest R&D unit in Central Eastern Europe, the Company’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in the scope of biosimilar product development.